Law360 (September 25, 2020, 8:45 PM EDT) -- Lawsuits alleging Johnson & Johnson's pharmaceutical unit concealed a harmful side effect of bladder cyst medicine Elmiron should be heard in New Jersey federal court due to the number of cases already filed there, a group of patients told the Judicial Panel on Multidistrict Litigation Friday.
The patients — seven couples and two individuals — cited judicial efficiency in their brief making a case for the transfer of all out-of-state Elmiron lawsuits to the Garden State, where 24 such actions are pending before U.S. District Judge Brian Martinotti. The suits accuse Janssen Pharmaceuticals Inc. of failing to warn consumers that Elmiron...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!